Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 drugs ...

The analyst points out that Eli Lilly’s success in this area is backed by several advantages that should help it maintain a leading position and market share in the furture. Even in Q4 2024 ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes ... On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

Thank you for joining us for Eli Lilly & Company's Q1 2025 earnings call ... of market increased by 5 percentage points compared to Q4 2024 and by 10 percentage points compared to the same ...